Fecal Microbiota Transplantation Is Effective for the Treatment of Partially Treated Clostridioides difficile Infection

Abstract

Fecal microbiota transplantation (FMT) is the infusion of feces from healthy donors to restore healthy microbiota. FMT has emerged as highly effective, safe, and costeffective treatment option for recurrent Clostridioides difficile infection (CDI) with a success rate around of 90%. In addition, FMT might be an encouraging therapeutic approach for the treatment of refractory, severe or complicated CDI and Clostridioides difficile ribotype 027. Based on these findings, multiple national and international consensus groups have included FMT as the standard of care for recurrent CDI. In Korea, there have been a few studies for the usefulness of FMT in this condition. In the Gut and Liver, Yoon et al. report clinical outcomes in patients with CDI who underwent FMT. In this study, 20 patients, including 45% of patients with fulminant CDI, were treated with fresh or frozen FMT. The overall success rate in this cohort was 55% after 1st FMT and 75% after 2nd FMT, and showed lower rates compared with those from meta-analyses. These findings may be attributed to inclusion of a number of severe or severe-complicated patients. It is unknown at what time point FMT should be performed. The researchers also performed FMT for the treatment of CDI patients who were not completely resolved after appropriate antibiotics therapy. Surprisingly, FMT had excellent treatment outcomes regardless of other factors in these patients with partially treated CDI, and the success rate was 100%. Studies for the use of FMT for primary CDI are very limited. A retrospective case series including CDI patients with ribotype 027 evaluated the efficacy of early FMT administered via a nasogastric tube within a week of infection in combination with antibiotics in patients with at least three treatment failures or relapses. The results showed early FMT was associated with significantly reduced mortality compared with using antibiotics only or delayed FMT, and only independent predictive factor of survival. But, 37.5% of patients undergoing early FMT needed 2nd FMT within a month following 1st FMT due to recurrence. A recent small pilot randomized trial compared the efficacy of FMT administered via enema (n=9) with oral metronidazole (n=11) as treatment for primary CDI. Although the study did not meet its primary endpoints, clinical cure observed in 78% of patients with FMT, compared with 45% of patients with metronidazole, suggesting that FMT might be an alternative treatment option to antibiotics as treatment of primary CDI. However, we need more studies including a large number of patients for FMT as initial treatment for CDI. Now, a phase 3 trial is underway to evaluate the efficacy of FMT as treatment for primary CDI. Mechanisms or microbial predictors underlying the efficacy of FMT remain uncertain. The characteristics of microbial profiles in CDI patients successfully treated with FMT include increased microbial diversity after FMT, recovery of community profiles to a level similar to those in the donor stools, decrease in some bacterial taxa including Proteobacteria and Fusobacteria, and increase in Firmicutes and Bacteroidetes. This study performed microbial analysis using 16S ribosomal RNA gene-based amplicon sequencing to determine the gut microbiota of recipients as well as donors. The results demonstrated changes of the microbial composition of recipient stools after FMT comparable to those from previous studies,